Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7512293 | 0.66 | CYP1A2 (0.59) | CYP1A2CCR1RAB9ACCR5KDM4E | |
| SCHEMBL8312831 | 0.65 | DYRK1A (0.46) | CYP1A2CCR1RAB9ACCR5KDM4E | |
| SCHEMBL207520 | 0.64 | CYP2A6 (0.44) | CYP1A2RAB9AKDM4E | |
| SCHEMBL7916567 | 0.64 | CYP1A2 (0.48) | CYP1A2RAB9AKDM4ELMNAPOLB | |
| SCHEMBL8337485 | 0.64 | CYP1A2 (0.40) | CYP1A2CCR1RAB9ACCR5KDM4E | |
| SCHEMBL9217980 | 0.62 | CYP1A2 (0.65) | CYP1A2CCR1RAB9ACCR5KDM4E | |
| SCHEMBL25244668 | 0.62 | CCR1 (0.34) | CYP1A2CCR1RAB9ACCR5 | |
| SCHEMBL1165531 | 0.61 | CYP1A2 (0.41) | CYP1A2RAB9AKDM4ELMNAPOLB | |
| SCHEMBL30528375 | 0.61 | CYP1A2 (0.41) | CYP1A2RAB9AKDM4ELMNAPOLB | |
| SCHEMBL295035 | 0.61 | CYP1A2 (0.54) | CYP1A2CCR1RAB9ACCR5KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111182898-B | Methods for treating huntington's disease | PTC医疗公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230310651-A1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4249472-A2 | METHODS FOR MODULATING RNA SPLICING | PTC Therapeutics, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230272367-A1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| EP-3644996-B1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11702646-B2 | Methods for modulating RNA splicing | PTC THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-3310169-B1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS INC (US) | 2023-05-17 | — | — | EP | disclosed |
| US-11602567-B2 | Methods for modulating RNA splicing | PTC THERAPEUTICS, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| US-9617268-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9586955-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20170000794-A1 | METHODS FOR MODULATING THE AMOUNT OF RNA TRANSCRIPTS | PTC THERAPEUTICS, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9399649-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9371336-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20150166575-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC. (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150126515-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-30 | — | — | US | disclosed |
| US-20150080383-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. | 2015-03-19 | — | — | US | disclosed |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | CYP1A2 4324/4885CCR1 4016/4885RAB9A 1350/4885 |
| US-20150005289-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | CYP1A2 4663/4885CCR1 4266/4885RAB9A 1728/4885 |
| US-20230272367-A1 | METHODS FOR MODULATING RNA SPLICING | RBM17, SNRPE, HNRNPM | CYP1A2 4151/4885CCR1 4765/4885RAB9A 2369/4885 |
| US-20150080383-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | CYP1A2 4663/4885CCR1 4266/4885RAB9A 1728/4885 |
| US-20150126515-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | CYP1A2 4663/4885CCR1 4266/4885RAB9A 1728/4885 |
| US-11702646-B2 | Methods for modulating RNA splicing | RBM17, SNRPE, HNRNPM | CYP1A2 4151/4885CCR1 4765/4885RAB9A 2369/4885 |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, RBM17, RBM22 | CYP1A2 4539/4885CCR1 3824/4885RAB9A 3292/4885 |
| US-11602567-B2 | Methods for modulating RNA splicing | RBM17, SNRPE, RBM3 | CYP1A2 4330/4885CCR1 4741/4885RAB9A 2689/4885 |
| US-20170000794-A1 | METHODS FOR MODULATING THE AMOUNT OF RNA TRANSCRIPTS | RNMT, NSUN2, RNGTT | CYP1A2 4410/4885CCR1 4277/4885RAB9A 3864/4885 |
| US-20150166575-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | CYP1A2 4663/4885CCR1 4266/4885RAB9A 1728/4885 |
| US-20230310651-A1 | METHODS FOR MODULATING RNA SPLICING | RBM17, SNRPE, RBM3 | CYP1A2 4330/4885CCR1 4741/4885RAB9A 2689/4885 |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, GYS1 | CYP1A2 4094/4885CCR1 3356/4885RAB9A 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.